sorrento
announces
intranasal
administration
neutralizing
antibody
prevented
disease
progression
infected
hamsters
following
infection
study
intranasal
nab
tm
early
decreased
disease
severity
shortened
duration
disease
infected
hamsters
early
decreased
disease
severity
shortened
duration
disease
infected
hamsters
sorrento
preparation
ind
filings
intranasal
nab
intravenous
nab
november
san
diego
globe
newswire
sorrento
therapeutics
nasdaq
srne
sorrento
previously
released
preclinical
data
intravenous
affinity
matured
neutralizing
antibody
nab
preprint
publication
found
https
cgi
content
short
today
sorrento
announced
enhancement
clinical
potential
antibody
releasing
vivo
data
intranasal
new
preprint
publication
found
https
content
preclinical
animal
data
generated
slobodan
paessler
laboratory
university
texas
medical
branch
utmb
galveston
syrian
golden
hamsters
infected
demonstrated
following
encouraging
results
hamsters
infected
median
tissue
culture
infectious
dose
intranasally
following
infection
animals
rested
hours
time
animals
administered
ug
dose
nab
either
intravenous
iv
intranasal
route
control
animals
administered
isotype
control
antibody
using
iv
regimens
median
tissue
culture
infectious
dose
intranasally
following
infection
animals
rested
hours
time
animals
administered
ug
dose
nab
either
intravenous
iv
intranasal
route
control
animals
administered
isotype
control
antibody
using
iv
regimens
animals
recovered
infection
noticeable
differences
weight
loss
control
igg
groups
reaching
maximum
infection
remarkably
animals
showed
evidence
early
experiment
prevention
disease
progression
limited
weight
loss
early
stages
infection
reduced
duration
disease
symptoms
compared
animals
simplicity
intranasal
administration
extremely
potent
neutralizing
antibody
would
permit
timely
massive
access
much
needed
antiviral
treatments
sorrento
optimistic
findings
hamster
model
infection
replicated
patients
planned
clinical
trials
could
position
potentially
open
society
preventing
virus
proliferation
spread
potentially
reduce
prevent
hospitalizations
even
hospital
visits
stated
henry
ji
chairman
ceo
sorrento
based
interspecies
allometric
scaling
methods
Âµg
single
dose
iv
administered
hamsters
preclinical
studies
would
equivalent
human
dose
approximately
mg
antibody
https
pmc
articles
sorrento
plans
investigate
intranasal
formulation
patients
recently
testing
positive
simple
intranasal
drops
image
accompanying
announcement
available
https
newsroom
attachmentng
illustrated
current
neutralization
antibodies
antibody
cocktails
known
development
fda
eua
approval
review
administered
large
amounts
often
grams
require
infusions
hours
hospital
setting
figure
sorrento
intravenous
nab
may
require
intravenous
slow
push
due
high
potency
demonstrated
animal
models
date
figure
furthermore
intranasal
may
able
administered
simple
intranasal
drops
figure
would
avoid
need
iv
infusion
injection
hospital
visit
treatment
sorrento
final
stages
cgmp
manufacture
forms
antibodies
anticipates
submitting
ind
filings
intravenous
intranasal
november
sorrento
intends
initiate
studies
healthy
volunteers
establish
pharmacokinetics
safety
also
initiating
studies
newly
infected
patients
demonstrate
safety
reduction
virus
load
symptoms
sorrento
therapeutics
sorrento
clinical
stage
biopharmaceutical
company
developing
new
therapies
treat
cancers
sorrento
multimodal
multipronged
approach
fighting
cancer
made
possible
extensive
platforms
including
key
assets
fully
human
antibodies
library
clinical
stage
therapies
conjugates
adcs
clinical
stage
oncolytic
virus
sorrento
also
developing
potential
antiviral
therapies
vaccines
coronaviruses
including
diagnostic
test
solutions
including
sorrento
commitment
therapies
patients
also
demonstrated
effort
advance
agonist
pain
management
small
molecule
resiniferatoxin
rtx
lidocaine
topical
system
treatment
neuralgia
rtx
completed
phase
trial
intractable
pain
associated
cancer
phase
trial
osteoarthritis
patients
approved
fda
february
information
visit
statements
press
release
statements
made
presentation
meeting
contain
statements
related
sorrento
therapeutics
safe
harbor
provisions
section
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
statements
regarding
potency
potential
blocking
capabilities
impact
preclinical
testing
safety
efficacy
expectation
commencement
clinical
trials
potential
trial
design
predictive
value
animal
model
used
preclinical
studies
human
equivalent
dose
may
required
potential
applications
potential
low
efficacious
dose
potentially
faster
efficient
manufacturing
speed
availability
potential
lower
cost
expected
methods
administration
expected
timing
submitting
ind
filings
sorrento
potential
position
antiviral
industry
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
statements
include
limited
risks
related
sorrento
subsidiaries
affiliates
partners
technologies
prospects
collaborations
partners
including
limited
risks
related
conducting
preclinical
studies
seeking
ind
regulatory
approval
conducting
receiving
results
clinical
trials
clinical
commercial
success
preventing
treating
virus
infections
viability
success
therapeutic
areas
including
coronaviruses
clinical
development
risks
including
risks
progress
timing
cost
results
clinical
trials
product
development
programs
risk
difficulties
delays
obtaining
regulatory
approvals
risks
clinical
study
results
may
meet
endpoints
clinical
study
data
generated
studies
may
support
regulatory
submission
approval
risks
prior
test
study
trial
results
may
replicated
future
studies
trials
risks
manufacturing
supplying
drug
product
risks
related
leveraging
expertise
employees
subsidiaries
affiliates
partners
assist
company
execution
therapeutic
product
candidates
strategies
risks
related
global
impact
risks
described
sorrento
recent
periodic
reports
filed
securities
exchange
commission
including
sorrento
annual
report
form
year
ended
december
subsequent
quarterly
reports
form
filed
securities
exchange
commission
including
risk
factors
set
forth
filings
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
required
law
contact
alexis
nahama
dvm
svp
corporate
development
email
mediarelations
sorrento
logo
registered
trademarks
sorrento
therapeutics
trademarks
sorrento
therapeutics
trademark
owned
scilex
pharmaceuticals
trademarks
property
respective
owners
sorrento
therapeutics
rights
reserved
